Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act
Authors:
Open Access
- 12 May 2016
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 60
Abstract
Rare rheumatologic diseases are a heterogeneous group of conditions associated with high morbidity. As a whole group, rare rheumatologic diseases afflict millions of people demanding for effective therapies. Therefore, we analyzed the impact of the US Orphan Drug Act on the development of anti-rheumatic orphan drugs. Analysis of the FDA database for orphan drug designations. In the last three decades, out of 77 orphan drug designations, 14 orphan drug approvals were granted by the FDA for the treatment of rare rheumatologic disorders, i.e. juvenile idiopathic arthritis (N = 5), cryopyrin-associated periodic syndromes (N = 3), uveitis (N = 3), familial Mediterranean fever (N = 1), anti-neutrophil cytoplasmic antibody-associated vasculitis (N = 1), and xerostomia and keratoconjunctivitis sicca in Sjögren’s syndrome (N = 1). Mean time (standard deviation) from designation to approval was 3.9 (2.81) [range 1 … 12] years. Number of FDA-approved small molecules (N = 6, 43 %) and biologics (N = 8, 57 %) was comparable. Almost every fifth (19 %) orphan drug designation was withdrawn. Despite the rarity of conditions, 13/14 pivotal studies were randomized controlled trials. Orphan drug development is challenging: thirty years of US orphan drug act supported the development and FDA approval of 14 orphan drug programs with anti-rheumatic compounds for six rheumatologic diseases.Keywords
This publication has 17 references indexed in Scilit:
- Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering—A Cross-Sectional AnalysisThe Oncologist, 2016
- Translation of rare disease research into orphan drug development: disease mattersDrug Discovery Today, 2009
- Clinical trials of orphan medicinesThe Lancet, 2008
- Does orphan drug legislation really answer the needs of patients?The Lancet, 2008
- Why rare diseases are an important medical and social issueThe Lancet, 2008
- Is there a future for small molecule drugs in the treatment of rheumatic diseases?Current Opinion in Rheumatology, 2008
- Solid malignancies among patients in the Wegener's granulomatosis etanercept trialArthritis & Rheumatism, 2006
- Exhaled nitric oxide in sarcoidosisThorax, 2005
- A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity ScoreArthritis & Rheumatism, 2001
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997